150 related articles for article (PubMed ID: 33172830)
1. Immune cell profiling in Gleason 9 prostate cancer patients treated with brachytherapy versus external beam radiotherapy: An exploratory study.
Wang H; Mendez LC; Morton G; Loblaw A; Mesci A; Chung HT; Chan S; Huang X; Downes MR; Vesprini D; Liu SK
Radiother Oncol; 2021 Feb; 155():80-85. PubMed ID: 33172830
[TBL] [Abstract][Full Text] [Related]
2. Brachytherapy for high grade prostate cancer induces distinct changes in circulating CD4 and CD8 T cells - Implications for systemic control.
Wang H; Mendez L; Morton G; Loblaw A; Chung HT; Cheung P; Mesci A; Escueta V; Petchiny TN; Huang X; White SD; Downes M; Vesprini D; Liu SK
Radiother Oncol; 2024 Feb; 191():110077. PubMed ID: 38176656
[TBL] [Abstract][Full Text] [Related]
3. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
[TBL] [Abstract][Full Text] [Related]
4. Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.
Sandler KA; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Song DY; Klein EA; Stephenson AJ; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco SC; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR; Kishan AU
Eur Urol; 2020 Jan; 77(1):3-10. PubMed ID: 30992160
[TBL] [Abstract][Full Text] [Related]
5. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
[TBL] [Abstract][Full Text] [Related]
6. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
Kishan AU; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Sandler KA; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Stephenson AJ; Klein EA; Song DY; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco S; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR
JAMA; 2018 Mar; 319(9):896-905. PubMed ID: 29509865
[TBL] [Abstract][Full Text] [Related]
7. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness and side effects of conformal external beam radiotherapy combined with high-dose-rate brachytherapy boost compared to conformal external beam radiotherapy alone in patients with prostate cancer.
Smolska-Ciszewska B; Miszczyk L; Białas B; Fijałkowski M; Plewicki G; Gawkowska-Suwińska M; Giglok M; Behrendt K; Nowicka E; Zajusz A; Suwiński R
Radiat Oncol; 2015 Mar; 10():60. PubMed ID: 25884489
[TBL] [Abstract][Full Text] [Related]
9. Quality of life up to 10 years after external beam radiotherapy and/or brachytherapy for prostate cancer.
Freiberger C; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M
Brachytherapy; 2018; 17(3):517-523. PubMed ID: 29496423
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of patients with localized and locally advanced prostate cancer undergoing high-dose-rate brachytherapy with external-beam radiotherapy at our institute.
Makino T; Mizokami A; Namiki M
Anticancer Res; 2015 Mar; 35(3):1723-8. PubMed ID: 25750334
[TBL] [Abstract][Full Text] [Related]
11. Survival Outcomes of Dose-Escalated External Beam Radiotherapy versus Combined Brachytherapy for Intermediate and High Risk Prostate Cancer Using the National Cancer Data Base.
Amini A; Jones B; Jackson MW; Yeh N; Waxweiler TV; Maroni P; Kavanagh BD; Raben D
J Urol; 2016 May; 195(5):1453-1458. PubMed ID: 26576709
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone.
Fang FM; Wang YM; Wang CJ; Huang HY; Chiang PH
Jpn J Clin Oncol; 2008 Jul; 38(7):474-9. PubMed ID: 18621848
[TBL] [Abstract][Full Text] [Related]
13. Brachytherapy or conformal external radiotherapy for prostate cancer: a single-institution matched-pair analysis.
Pickles T; Keyes M; Morris WJ
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):43-9. PubMed ID: 19570619
[TBL] [Abstract][Full Text] [Related]
14. The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis.
Shen X; Keith SW; Mishra MV; Dicker AP; Showalter TN
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1154-9. PubMed ID: 22270175
[TBL] [Abstract][Full Text] [Related]
15. The Cancer of the Prostate Risk Assessment (CAPRA) score predicts biochemical recurrence in intermediate-risk prostate cancer treated with external beam radiotherapy (EBRT) dose escalation or low-dose rate (LDR) brachytherapy.
Krishnan V; Delouya G; Bahary JP; Larrivée S; Taussky D
BJU Int; 2014 Dec; 114(6):865-71. PubMed ID: 24274784
[TBL] [Abstract][Full Text] [Related]
16. Comparison between external beam radiotherapy (70 Gy/74 Gy) and permanent interstitial brachytherapy in 890 intermediate risk prostate cancer patients.
Goldner G; Pötter R; Battermann JJ; Kirisits C; Schmid MP; Sljivic S; van Vulpen M
Radiother Oncol; 2012 May; 103(2):223-7. PubMed ID: 22398311
[TBL] [Abstract][Full Text] [Related]
17. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
[TBL] [Abstract][Full Text] [Related]
18. Prostatic acid phosphatase adversely affects cause-specific survival in patients with intermediate to high-risk prostate cancer treated with brachytherapy.
Fang LC; Dattoli M; Taira A; True L; Sorace R; Wallner K
Urology; 2008 Jan; 71(1):146-50. PubMed ID: 18242384
[TBL] [Abstract][Full Text] [Related]
19. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
20. External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.
Wang C; Kishan AU; Kamrava M; Steinberg ML; King CR
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1045-1052. PubMed ID: 28721887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
